| Name | JTE-013 |
| Description | JTE-013 is an effective and specific antagonist of S1P2. JTE-013 suppresses the specific binding of radiolabeled S1P to human and rat S1P2 (IC50s: 17 nM and 22 nM, respectively). |
| In vitro | JTE-013 is a S1P2 antagonist. JTE-013 (50-200 μM;?1-3 days) decreased cell viability.?JTE-013 shows 4.2% inhibition of S1P3 and does not antagonize S1P1 at concentrations up to 10 μM.?JTE-013 (10-1000 nM;?30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation. |
| In vivo | JTE-013 (gavage;?30 mg/kg daily for 14 consecutive days) decreases tumor size and tumor weight.?the modification of JTE-013 to produce the AB1 compound improved potency, intravenous pharmacokinetics, cellular activity, and antitumor activity in NB and may have enhanced clinical and experimental applicability. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (612.31 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (8.08 mM), Sonication is recommended.
|
| Keywords | S1PReceptor | S1P2 for rat | S1P2 for human | S1P2 | S1P Receptor | Lysophospholipid Receptor | LPLReceptor | LPL Receptor | LPL | JTE-013 | JTE013 | JTE 013 | Inhibitor | inhibit | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Viral Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Infection Compound Library |